Havas’ GLP-1 Consultancy takes center stage at 1 Billion Followers Summit in Dubai
As GLP-1 adoption accelerates across the Middle East, Havas brings a unique specialized strategic cultural lens to the rapidly evolving metabolic economy
Baseline Therapeutics Launches to Advance GLP-1RA Phase 3 Program in Alcohol Use Disorder
SAN FRANCISCO–(BUSINESS WIRE)– #SUD–Baseline Therapeutics, Inc. (“Baseline”), a clinical-stage biotechnology company developing addiction therapeutics, today announced the launch of the company to advance a new generation of pharmacotherapies for substance use disorders. Baseline’s lead program, BT-001, is a best-in-class, once-weekly GLP-1 receptor agonist (GLP-1RA) candidate being developed for alcohol use disorder (AUD), with additional substance […]
GLP-1 Meds Are Bringing Back Our Eating Disorders
STAT+: New startup to develop a GLP-1 drug for addiction
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. A new startup focused on GLP-1 drugs launched today, but unlike the dozens of other GLP-1 companies, this one isn’t studying weight loss. The need-to-know this morning Roche plans to launch Phase […]
Where Will Eli Lilly Be in 10 Years?
Key Points The pharmaceutical industry has a well-structured cycle. Eli Lilly is currently benefiting from the early stages of the cycle. In 10 years, if not sooner, investors will begin to worry about Eli Lilly’s future beyond GLP-1 drugs. 10 stocks we like better than Eli Lilly › If you follow the news at all, […]
Donald Trump couldn’t remember the word ‘Alzheimer’s,’ his father’s condition
Instead of focusing on Donald Trump’s profound cognitive decline and his visibly terrible health during the 2024 election, the media has only *really* started talking about Trump’s health in the past year. They have to be dragged kicking and screaming into the discussion too, because they really couldn’t care less about their despicable double-standards and […]
Do GLP-1s Have Deleterious Effects on Muscle?
Emerging evidence suggests that GLP-1 receptor agonists may improve muscle quality as body weight and lean mass decline. Medscape Gastroenterology
Roche, trailing in obesity, showcases new data for GLP-1 shot
A drug Roche acquired in a multibillion-dollar deal could be as effective as Zepbound, but may struggle to stand out in a crowded field, analysts said.
Genentech Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living With Obesity
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP receptor agonist being developed for the treatment of obesity. The study found that once-weekly subcutaneous injections of CT-388 (titrated up to […]
[Ad hoc announcement pursuant to Art. 53 LR] Roche announces positive Phase II results for its dual GLP-1/GIP receptor agonist CT-388 in people living with obesity
A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p < 0.001) at 48 weeks at the highest dose tested (24 mg), without reaching a weight loss plateau 54% of participants on the 24 mg dose achieved resolution of obesity (BMI <30 kg/m2) vs. 13% in the placebo group […]